about
An Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeConsequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursorsSkeletal and hormonal effects of magnesium deficiencyRheumatology: 15. OsteoporosisLong-term Effects of Antihypertensive Drug Use and New-onset Osteoporotic Fracture in Elderly Patients: A Population-based Longitudinal Cohort StudyConstant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms.Parathyroid hormone (hPTH 1-38) stimulates the expression of UBP41, an ubiquitin-specific protease, in bone.Persistent mucosal damage and risk of fracture in celiac disease.Current and potential future drug treatments for osteoporosis.Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure.Osteoporosis: "A risk factor for periodontitis"Iron Deficiency Anemia as a Risk Factor for Osteoporosis in Taiwan: A Nationwide Population-Based Study.Prevalence and predictors of osteoporosis risk in orthopaedic patientsFactors associated with treatment of women with osteoporosis or osteopenia from a national survey.Reproductive aging and risk for chronic disease: Insights from studies of nonhuman primatesThe diurnal rhythm of bone resorption in the rat. Effect of feeding habits and pharmacological inhibitors.Features of asthma in the elderly.Bone mineral density in coeliac disease.Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease.Protein intake and bone growth.N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow.Ospemifene use in postmenopausal women.In vitro heterogeneity of osteogenic cell populations at various equine skeletal sitesFemoral Shaft Cortical Pathology associated with longterm Alendronate Therapy: A New ClassificationPostmenopausal hormone replacement therapy.Overview of osteoporosis: pathophysiology and determinants of bone strengthIntravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.Exercise and estrogen or estrogen alternatives (phytoestrogens, bisphosphonates)for preservation of bone mineral in postmenopausal women.A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.Osteoporosis: the increasing role of the orthopaedist.Local pamidronate influences fracture healing in a rodent femur fracture model: an experimental study.Bisphosphonate-associated femur fractures have high complication rates with operative fixation.Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies.Associations of Education Level and Bone Density Tests among Cognitively Intact Elderly White Women in Managed MedicareLow molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studiesBone mineral density changes during the menopause transition in a multiethnic cohort of women.Hormone replacement therapy. Risks, benefits, and costs.[Osteoporosis in 1993. An information update].Chronic Kidney Disease Impairs Bone Defect Healing in Rats
P2860
Q24791238-290C3D74-434F-43DC-934D-3C236A62D220Q26864483-CF8EF68A-854D-4FB0-A451-9BE41C7F9768Q28261418-4E5FE233-26F0-4CC1-94CC-908BF12A357FQ28344803-4C76AE82-DF6D-46E0-891B-DB5E2DD510D4Q28468516-709E3431-345A-42A5-8170-6C183297A49CQ32065283-0A9BC37E-1134-43AE-B2D0-97A61C6203CBQ32081257-84CA529B-490F-488F-BD01-8E967582D4E9Q33570033-D3FD2C9C-CDB4-475C-B9CE-D722A953B4E5Q33579316-444C9400-7FB2-40CC-BF70-2394639CB653Q33684739-FD2F2CE2-A2B0-4400-B5BF-E6EB7E18692EQ33759893-AFCA2A48-734E-4EE5-B520-62F10C8E255DQ33852114-E7FCAF02-5114-4E16-AE47-E047B6254414Q33898779-D08C05FF-416C-401E-ACFD-AF66FCBCCB00Q34120838-F1383E46-0E35-4D93-A747-9EEB7BB5E0EEQ34139555-69B5DA09-D38D-4860-A757-61A442C8A417Q34212461-014897D0-6959-41E9-A6C6-7D2F37BABE4AQ34342751-0BE1A975-7EA5-432F-B8D8-B5E8B41918C9Q34377840-0F845FF6-9D82-4F34-9793-1B71BCD33150Q34408449-C54FD5E8-2DBB-4441-AF59-663149880F99Q34565780-43214700-8AB4-446C-BF86-905A14D0A174Q34948033-4DB4134B-1164-4FDA-BCB0-9DF7B581BFB7Q34982860-383488E8-8956-4AF0-B3EE-4212D4D0AAF0Q35021766-DB215716-8B9E-4338-A036-26EAB50F8B75Q35123236-BB897429-CEE9-42C0-A757-E057D77BD857Q35245034-D34E6171-C626-4A26-BE49-1A1575428165Q35299189-5B6F6669-7CF2-486C-9B18-06B1703BC8CEQ35552068-F03F1EE9-F09E-486C-B26A-2F182C264CFCQ35682935-4C8233F7-33EE-4D66-8081-62A54906D3A6Q35826528-7D5B4E59-E487-4F8A-A807-8938C89DFE61Q35836987-DBB02FFC-A0AD-4DE8-A690-BC03B58CDC52Q36047570-8FEB5322-686F-42BE-BF4F-8666DB663628Q36083736-8828B8B9-1852-4C6F-985D-D5636643289CQ36115270-FBC5BBCF-F5D2-4A95-97BA-66BBFBD114FDQ36271670-05500E08-62BE-4109-89C2-6C7BDCDD9057Q36296405-1B8386BC-44A9-4EE9-AD6A-BD3934A6A577Q36452196-13C1BDFD-3484-416B-BD4D-C05375A4F43AQ36494395-D989E399-7DC1-4E80-839E-6E38BB34C8DBQ36652768-B24DC1A4-FDCE-475C-BC75-0ED0B78F660AQ36653023-035B91AA-5B75-4A93-84D1-9205B176CA89Q36666522-CDBE58E6-3B60-4278-B348-74F8D43958B4
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
The prevention and treatment of osteoporosis.
@ast
The prevention and treatment of osteoporosis.
@en
type
label
The prevention and treatment of osteoporosis.
@ast
The prevention and treatment of osteoporosis.
@en
prefLabel
The prevention and treatment of osteoporosis.
@ast
The prevention and treatment of osteoporosis.
@en
P1476
The prevention and treatment of osteoporosis.
@en
P2093
Melton LJ 3rd
P304
P356
10.1056/NEJM199208273270908
P407
P577
1992-08-01T00:00:00Z